Information Provided By: 
Fly News Breaks for May 20, 2015
SRPT
May 20, 2015 | 07:36 EDT
As previously reported, Canaccord upgraded Sarepta to Buy from Hold citing reduced near-term regulatory risk and upcoming catalysts following the company's positive pre-NDA meeting with the FDA for eteplirsen, the company's Duchenne muscular dystrophy drug. Canaccord raised its price target to $30 from $16 on Sarepta shares, which are up more than 46% to $24 in pre-market trading.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
